GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » EV-to-EBIT

PYXS (Pyxis Oncology) EV-to-EBIT : 0.18 (As of Jul. 22, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Pyxis Oncology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pyxis Oncology's Enterprise Value is $-15.59 Mil. Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-85.81 Mil. Therefore, Pyxis Oncology's EV-to-EBIT for today is 0.18.

The historical rank and industry rank for Pyxis Oncology's EV-to-EBIT or its related term are showing as below:

PYXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.15   Med: 0.04   Max: 0.74
Current: 0.18

During the past 6 years, the highest EV-to-EBIT of Pyxis Oncology was 0.74. The lowest was -2.15. And the median was 0.04.

PYXS's EV-to-EBIT is ranked better than
91.42% of 431 companies
in the Biotechnology industry
Industry Median: 12.38 vs PYXS: 0.18

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Pyxis Oncology's Enterprise Value for the quarter that ended in Mar. 2025 was $-25.20 Mil. Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-85.81 Mil. Pyxis Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 340.53%.


Pyxis Oncology EV-to-EBIT Historical Data

The historical data trend for Pyxis Oncology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology EV-to-EBIT Chart

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial - -1.13 0.92 0.21 0.19

Pyxis Oncology Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.71 -0.87 -1.40 0.19 0.29

Competitive Comparison of Pyxis Oncology's EV-to-EBIT

For the Biotechnology subindustry, Pyxis Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pyxis Oncology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pyxis Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pyxis Oncology's EV-to-EBIT falls into.


;
;

Pyxis Oncology EV-to-EBIT Calculation

Pyxis Oncology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-15.589/-85.805
=0.18

Pyxis Oncology's current Enterprise Value is $-15.59 Mil.
Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-85.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pyxis Oncology  (NAS:PYXS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Pyxis Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-85.805/-25.1977831
=340.53 %

Pyxis Oncology's Enterprise Value for the quarter that ended in Mar. 2025 was $-25.20 Mil.
Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-85.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pyxis Oncology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Pyxis Oncology Business Description

Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, Boston, MA, USA, 02118
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Executives
Pamela Ann Connealy officer: Chief Financial Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane officer: Chief Accounting Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan director, officer: Chief Executive Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin other: Former Director 20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v. 10 percent owner ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst officer: Chief Scientific Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140